ANTECH
23.4.2024 08:01:29 CEST | Business Wire | Press release
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Science & Diagnostics said: “It’s exciting to see innovations like Nu.Q® Canine Cancer Test become more widely available to veterinary teams in Europe. With cancer affecting one in four dogs1, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes. This is what our work at Antech is all about.”
Nu.Q® Canine Cancer Test is a breakthrough technology that measures circulating nucleosomes, supporting earlier cancer detection in some of the most prevalent types of canine cancers. Nu.Q® testing, run on the Element i+ analyser, is both cost-effective and simple, requiring only 50µL of EDTA plasma from a patient and providing accurate results in 5 to 10 minutes. Studies2 have shown >75% detection rates for common cancers in dogs like lymphoma and hemangiosarcoma when using Nu.Q®. As the only patient-side in-house test that provides rapid and accurate results from EDTA plasma, the Nu.Q® test is an aid to diagnosis that can be run in clinic by veterinary professionals during annual check-ups or regular senior wellness exams.
Dr. Maximiljan W. Krauss, Dipl. ECVS, Tierklink Düsseldorf, used Nu.Q® Canine Cancer Test first-hand during the pilot phase and commented: “At our clinic, we see around 1500 cases of cancer in dogs a year. Lymphoma and hemangiosarcoma are the most common type of cancer we see affecting dogs as young as five years old. Thanks to Nu.Q® Canine Cancer Test and the Element i+ in-house analyzer, we have a fast and accurate means to screen for cancer, which helps us intervene early and choose the best possible care pathway for every patient. At the end of the day, early interventions can make a real difference to a dog’s quality of life and the time they have to spend with their family.”
Nu.Q® is a registered trademark of VolitionRx Limited and its subsidiaries. The Nu.Q® Canine Cancer Test is supplied under license by Belgian Volition SRL.
Nu.Q® will be available in the UK as part of the European launch. For orders and more information about the product, please contact Antech UK.
About Mars Science & Diagnostics and Antech
Mars Science & Diagnostics is a division of Mars Petcare, a diverse business dedicated to one purpose: A BETTER WORLD FOR PETS™. Science & Diagnostics brings together the power of leading pet health science with expertise across diagnostics, data, and technology to improve outcomes in pet health. Our veterinary diagnostics business, Antech, spans in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; 90+ reference laboratories around the globe; veterinary imaging and technology; education; and board-certified specialist support services. Our at-home diagnostics offering includes Wisdom Panel™ DNA test products, the world’s most accurate pet DNA test. For 60 years, our Waltham Petcare Science Institute has been advancing science to better understand pet health.
2 Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022). https://doi.org/10.1186/s12917-022-03429-8
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240422725707/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amadeus Explores Next-Generation Flight Search with NVIDIA21.10.2026 14:00:00 CEST | Press release
Amadeus and NVIDIA have been collaborating to explore how accelerated computing and travel-specific AI could support faster, more scalable and more efficient flight search. Building on this work, the companies have now signed a Memorandum of Understanding (MoU) to deepen their collaboration and accelerate further exploration. As AI assistants increasingly search on behalf of travelers, they are changing both the volume and complexity of demand placed on travel technology. Amadeus, in collaboration with NVIDIA, have already conducted initial technical assessments and benchmarking activities, on the NVIDIA Hopper and Blackwell platform, NVIDIA's accelerated computing architectures designed for AI and high-performance computing workloads, to better understand how accelerated computing could support large-scale travel shopping workloads. Through the MoU, Amadeus and NVIDIA will continue this collaboration, with aims to deliver faster, more scalable and more efficient flight search as AI-po
TreviPay Expands Pay by Invoice Availability for Walmart Business Customers21.10.2026 14:00:00 CEST | Press release
The general availability gives eligible organizations more flexibility with net 30-day terms, a dedicated business line of credit and streamlined reconciliation TreviPay, a global B2B payments infrastructure partner, today announced the general availability of Pay By Invoice for eligible Walmart Business customers. Following an initial pilot, the expanded availability gives more organizations a new way to manage purchasing and payments online and in Walmart stores. Walmart Business Pay By Invoice provides net 30-day terms, a dedicated business line of credit and detailed invoicing built into the Walmart Business purchasing experience. Powered by TreviPay, Walmart Business Pay By Invoice is designed to give organizations greater flexibility in how they manage business purchases and payments. Eligible customers can get what they need and pay on net 30-day terms, helping them preserve cash flow for other priorities while keeping operations moving. Purchasing controls and payment reconcili
Global Network for the Advancement of Metabolic Psychiatry (MetPsy) Launches with $20 Million Investment in Clinical Care, Education and Research at McLean Hospital21.10.2026 14:00:00 CEST | Press release
Baszucki Group funding awarded to McLean Hospital to establish a flagship clinical and research center, and jointly to McLean and MH² for medical education and training initiatives Baszucki Group today announced the launch of the Global Network for the Advancement of Metabolic Psychiatry (MetPsy), uniting researchers and clinicians worldwide to advance evidence-based practice in metabolic psychiatry through clinical care, education, and research. The launch is accompanied by a new $20 million grant from Baszucki Group to build a clinical and research center at McLean Hospital, a member of Mass General Brigham, creating the infrastructure to deliver metabolic approaches to psychiatric care at scale. The grant also supports medical education and training initiatives co-led by MH², a clinical practice, training and education hub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021217733/en/ MetPsy, a global network for metabo
Starburst Introduces Starburst Torin, a GPU-Native Analytics Engine Built on NVIDIA cuDF21.10.2026 13:30:00 CEST | Press release
Starburst Torin runs SQL natively on NVIDIA GPUs, delivering up to 7x faster query performance to accelerate AI agents and enable data teams to run more workloads without moving data or changing existing SQL or applications. Starburst today announced limited general availability of Starburst Torin, a GPU-native, Trino-based analytics engine for Starburst Enterprise. Built on NVIDIA cuDF, Torin accelerates SQL workloads with native GPU execution, delivering up to 7x faster query performance.1 By complementing Starburst’s existing CPU engine, Torin gives enterprises the flexibility to run workloads on CPUs or GPUs without changing existing Trino SQL queries, applications, or agents. AI agents create a different kind of load on data platforms. A single agent task can trigger a chain of dependent queries, where delays in one query can slow the entire workflow. These bottlenecks also affect interactive analytics, making it harder to explore data, evaluate results, and make decisions in real
Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 202621.10.2026 12:47:00 CEST | Press release
Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to support testing under more physiological conditions. The commercial launch follows Compvide’s participation in the 20th European Meeting on Complement in Human Disease (EMCHD), held September 1–5, 2026, in Cardiff, Wales. Through a scientific presentation, poster, and exhibition, the company shared research highlighting the importance of assay conditions in evaluating complement activity and the effects of complement-targeting therapies. Unlike conventional assays that often use highly diluted serum, CIMED assays use 50% serum. Research presented by Compvide at EMCHD highlighted how serum dilution can influence measurements of complement inhibition, particularly at lower drug concentrations. These findings underscore the importance of assay conditions when evaluating pote
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom